Apogee Therapeutics, Inc. (NASDAQ: APGE) has expanded its board of directors with the appointment of Lisa Bollinger, MD, a seasoned professional with over 30 years of experience in drug development and deep regulatory insight. Prior to joining Apogee, Dr. Bollinger served as the Vice President of Regulatory Affairs and Clinical Safety at Merck, leading the general medicine therapeutic area in regulatory affairs.
Apogee is at an exciting juncture with two programs already in clinical development and a third expected in the second half of 2024. This expansion comes at a pivotal time for the company as it gears up for potential future approvals. Dr. Bollinger's extensive experience in diverse functions across the healthcare industry makes her an ideal addition to the board of directors.
Dr. Bollinger's career spans various roles at Amgen, where she focused on global regulatory affairs and safety, with a particular emphasis on pediatrics. Her tenure at the U.S. Food and Drug Administration (FDA) and her clinical expertise from the pharmaceutical industry have equipped her with unique insights into regulatory intricacies.
In her own words, Dr. Bollinger expressed her admiration for Apogee's rapid progress in advancing its differentiated pipeline of programs for diseases with high unmet need, particularly atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD). The company's pipeline aims to offer potentially greater efficacy and less frequent dosing regimens, particularly in the pediatric population.
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma, and other inflammatory and immunology indications with high unmet need. The company's antibody programs are designed to address the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company's two most advanced programs, APG777 and APG808, are initially being developed for the treatment of atopic dermatitis and COPD, respectively. The market has reacted to these announcements by moving the company's shares -1.9% to a price of $47.13. If you want to know more, read the company's complete 8-K report here.
